查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1996527

病毒载体生产市场：2026年至2032年全球市场预测（按载体类型、工作流程、递送方式、技术、疾病、应用和最终用户划分）

Viral Vector Manufacturing Market by Vector Type, Workflow, Delivery Method, Technology, Disease Indication, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，病毒载体生产市场价值将达到 110 亿美元，到 2026 年将成长至 131.7 亿美元，到 2032 年将达到 410 亿美元，复合年增长率为 20.67%。

主要市场统计数据
基准年 2025 110亿美元
预计年份：2026年 131.7亿美元
预测年份：2032年 410亿美元
复合年增长率 (%) 20.67%

简洁扼要、权威详尽地概述了塑造现代病毒载体生产的科学进步、监管预期和营运现实。

病毒载体生产正处于一个关键的十字路口，科学创新、商业性发展动能和操作规范在此交会。载体设计、细胞培养系统和纯化技术的最新进展拓展了治疗的可能性，同时也把生产复杂性提升到了一个新的水平。如今，研发人员和生产商面临着不断变化的监管要求、更严格的品管，以及生物製药规模化生产所带来的技术挑战，这些挑战必须确保整个生产批次的疗效和安全性。

对病毒载体生产中重新定义生产能力、品质系统和人员需求的技术、监管和商业性变革进行详细分析。

病毒载体生产领域正经历着由技术、监管和商业因素共同驱动的变革。在技​​术层面，转染和纯化技术的创新提高了产量、杂质控制和产品一致性的标准。这促使各企业重新评估其平台选择，并采用混合製程架构，将反应器的可扩展性与新兴的一次性及连续下游解决方案相结合。随着製程的演进，品质体係也在不断发展，先进的线上製程分析和即时放行检测在展现控制能力和加速产品开发进程方面发挥核心作用。

对近期美国关税措施如何重塑筹资策略、供应商韧性和区域製造本地化选择进行全面分析。

2025年，美国关税措施带来了额外的成本和供应链复杂性的增加，影响波及整个病毒载体生产生态系统。这些关税影响了关键原料、一次性抛弃式产品和专用设备的筹资策略，促使各企业重新评估供应商选择，并探索替代采购管道。因此，製造商越来越注重确保供应商资格的冗余性、关键零件的近岸外包以及策略性库存管理，以维持生产的连续性。

详细的細項分析揭示了载体生物学、工作流程结构、剂型、底层技术、治疗适应症、应用和最终用户概况如何决定製造策略。

細項分析揭示了载体生物学特性、工作流程阶段、递送方式、底层技术、治疗重点、应用以及最终用户特征等因素所带来的细微差别和营运优先事项。依载体类型划分，市场可分为腺病毒载体、桿状病毒载体、单纯疱疹病毒载体、慢病毒载体、质体DNA及逆转录病毒。每种载体都有其独特的嗜性、有效载荷能力以及下游纯化过程中面临的纯度挑战，这些都会影响製程设计和分析需求。按工作流程划分，市场可分为下游工艺和上游工艺，其中下游工艺进一步细分为製剂和纯化，上游工艺进一步细分为反应器、细胞培养系统和培养基配方。这种细分突出表明，上游製程的选择（例如细胞培养系统）会直接影响下游纯化负荷和製剂稳定性要求。

针对美洲、欧洲、中东和非洲以及亚太市场的製造能力、监管复杂性和供应链韧性进行战略区域展望。

区域趋势持续对生产策略、监管合作和商业发展产生关键影响。在美洲，雄厚的创业投资资金、先进的临床研发管线和完善的契约製造基础设施支援专案快速推进，但成本压力和贸易政策考量要求供应链设计必须谨慎。在欧洲、中东和非洲，协调监管的努力与各国不同的要求并存，迫使製造商建立灵活的品质体系，并利用区域合约生产组织（CMO）网路来应对不同的核准流程。在亚太地区，对生物加工能力的投资和不断扩大的国内供应商基础正在拓宽本地生产选择，并加速该地区临床试验和商业供应的本地化生产。

对竞争格局进行策略评估，展现流程专业知识、整合平台供应商和合作伙伴关係如何重塑能力和生产能力的竞争格局。

病毒载体生产生态系统中的主要企业凭藉其在製程开发、规模化生产、分析服务和生产能力方面的差异化优势，正引领着产业发展。成熟的契约製造製造商不断整合先进的纯化平台和模组化无尘室解决方案，以满足客户多样化的需求，从而持续扩大产能并提升技术服务水准。同时，生物技术创新者不断突破载体设计和转染化学的界限，催生了对专业製程开发伙伴关係和客製化分析方法的需求。

为领导者提供切实可行的营运和策略建议，以加强韧性、品质系统、区域生产能力选择以及病毒载体製造的技术投资。

为了将洞察转化为营运优势，产业领导者应优先采取一系列针对性行动，并专注于韧性、品质和策略​​投资。首先，平台选择应与预期的临床和商业性前景相匹配，确保载体类型和递送方式的选择有检验的上游和下游製程设计作为支撑。其次，投资于关键耗材和设备的供应商合格和双源采购策略，以减轻贸易措施和物流中断的影响。第三，加快采用製程分析技术和数位控制系统，以减少週期波动并实现数据驱动的放行策略。

我们采用透明、多方面的研究途径，结合一手访谈、技术文献综述和跨案例分析，得出实用的製造见解。

本综合报告采用多方面方法，结合了深度访谈、技术文献综述以及监管指南和行业实践的比较分析。深入研究包括与製程开发科学家、生产经理、品质保证专家和采购负责人进行结构化访谈，以确定实际限制因素、推广驱动因素和营运重点。此外，还参考了同行评审期刊、技术白皮书和公开的监管文件等二级资讯来源，以确保技术和合规性声明符合当前标准和科学共识。

这一简洁而前瞻性的结论总结了实现稳健、可扩展和合规的病毒载体生产的战略挑战。

总而言之，病毒载体生产正从手工、专案特定的生产方式转向更工业化、以品质为中心的营运模式，以满足多种治疗方法。这一转变是由纯化和转染技术的进步、不断变化的监管预期以及从研发到供应都需要敏捷性的商业性趋势共同推动的。关税导致的采购趋势变化凸显了弹性供应商网路和区域生产策略的重要性，而细分市场分析则强调，最佳製程设计必须根据载体类型、工作流程配置、给药方法、技术选择、适应症、应用和最终用户需求量身定制。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：病毒载体生产市场：依载体类型划分

  • 腺病毒载体
  • 桿状病毒载体
  • 单纯疱疹病毒载体
  • 慢病毒载体
  • 质体DNA
  • 逆转录病毒

第九章：病毒载体生产市场：依工作流程划分

  • 下游工艺
    • 配方
    • 纯化
  • 上游工艺
    • 反应器
    • 细胞培养系统
    • 培养基製备

第十章：病毒载体生产市场：依递送方式划分

  • Ex vivo
    • 细胞再输注
    • 细胞转导
  • In vivo
    • 直接注射
    • 静脉注射
    • 口服

第十一章：病毒载体生产市场：依技术划分

  • 炼油技术
    • 层析法
    • 超过滤
  • 转染方法
    • 化学方法
    • 电穿孔

第十二章：病毒载体生产市场：依疾病分类

  • 心血管疾病
  • 遗传性疾病
  • 感染疾病
  • 代谢性疾病

第十三章：病毒载体生产市场：依应用划分

  • 基因治疗
    • 遗传性疾病
    • 肿瘤性疾病
    • 单基因突变
  • 肿瘤学调查
    • 基因惰性
    • 溶瘤病毒疗法
    • 肿瘤抑制基因
  • 疫苗学
    • 癌症疫苗
    • 感染疾病
    • 通用感染疾病

第十四章：病毒载体生产市场：依最终用户划分

  • 生技公司
    • 大公司
    • Start-Ups
  • 製药公司
    • 製造业
    • 研究与开发
  • 研究机构
    • 学术实验室
    • 政府附属实验室

第十五章：病毒载体生产市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：病毒载体生产市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章：病毒载体生产市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国病毒载体生产市场

第十九章：中国病毒载体生产市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ABL Inc.
  • Batavia Biosciences BV （CJ Cheiljedang）
  • Biovian Oy
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Danaher Corporation
  • FinVector Oy
  • FUJIFILM Diosynth BIoTechnologies USA, Inc.
  • GE HealthCare Technologies, Inc.
  • Genezen Laboratories, Inc.
  • Kaneka Eurogentec SA
  • Lonza Group Ltd.
  • MaxCyte, Inc.
  • Merck KGaA
  • Miltenyi BIoTec GmbH
  • Novartis AG
  • Oxford Biomedica PLC
  • Sanofi SA
  • Sirion-BIoTech GmbH
  • Spark Therapeutics, Inc. （F. Hoffmann-La Roche Ltd.）
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uniQure NV
  • VGXI, Inc. by GeneOne Life Science
  • Waisman Biomanufacturing
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-FD3F12D54086

The Viral Vector Manufacturing Market was valued at USD 11.00 billion in 2025 and is projected to grow to USD 13.17 billion in 2026, with a CAGR of 20.67%, reaching USD 41.00 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.00 billion
Estimated Year [2026] USD 13.17 billion
Forecast Year [2032] USD 41.00 billion
CAGR (%) 20.67%

A concise, authoritative introduction connecting scientific advances, regulatory expectations, and operational realities shaping contemporary viral vector manufacturing

Viral vector manufacturing stands at a pivotal juncture where scientific innovation, commercial momentum, and operational rigor intersect. Recent advances in vector design, cell culture systems, and purification methodologies have expanded therapeutic possibilities while simultaneously introducing new layers of manufacturing complexity. Developers and manufacturers now confront evolving regulatory expectations, heightened quality controls, and the technical demands of scaling biologics that must preserve potency and safety across production runs.

As stakeholders respond to these pressures, investments in automation, single-use bioprocessing, and analytic platforms are reshaping factory footprints and skill requirements. This introduction contextualizes the current landscape by connecting scientific drivers to practical manufacturing realities, emphasizing that success depends on integrating process robustness with regulatory foresight. It further highlights the need for cross-functional collaboration among research, process development, quality, and supply chain teams to translate laboratory promise into reliable clinical and commercial supply.

Understanding these dynamics is essential for senior executives and operational leaders who must balance time-to-clinic imperatives with sustainable manufacturing strategies. The following sections unpack transformative shifts, policy impacts, segmentation-specific insights, and regionally differentiated considerations that together form a strategic picture of contemporary viral vector manufacturing.

An in-depth exploration of the technological, regulatory, and commercial transformations redefining capacity, quality systems, and workforce needs across viral vector manufacturing

The viral vector manufacturing landscape is undergoing transformative shifts driven by converging technological, regulatory, and commercial forces. On the technological front, innovations in transfection methods and purification techniques are raising the bar for yield, impurity control, and product consistency. This has led organizations to reassess platform choices and to adopt hybrid process architectures that marry the scalability of bioreactors with emerging single-use and continuous downstream solutions. As processes evolve, so too do quality systems; advanced in-process analytics and real-time release testing are becoming central to demonstrating control and enabling accelerated development pathways.

Regulatory evolution is another major factor, with authorities emphasizing risk-based approaches, lifecycle oversight, and supply chain transparency. Consequently, developers are prioritizing design spaces that facilitate comparability, change control, and post-approval process flexibility. Commercial dynamics also contribute to change: as clinical programs proliferate across gene therapy, oncology research, and vaccinology, demand profiles have become more heterogeneous, requiring adaptable manufacturing capacities that can support smaller, high-complexity runs alongside larger-scale campaigns.

Operationally, workforce composition and competency models are shifting to include a larger share of process analytics, regulatory scientists, and specialists in biologics engineering. Meanwhile, strategic partnerships, contract development and manufacturing relationships, and modular facilities are emerging as preferred mechanisms to de-risk capacity investments. Taken together, these shifts indicate a sector moving from one-off, lab-scale production toward industrialized, quality-driven manufacturing that supports diverse therapeutic modalities at varying scales.

A comprehensive analysis of how recent United States tariff measures have reshaped procurement strategies, supplier resilience, and regional manufacturing localization choices

In 2025, tariff policies in the United States introduced additional costs and supply chain complexities that reverberated across viral vector manufacturing ecosystems. These tariffs have impacted the sourcing strategies for critical raw materials, single-use disposables, and specialized equipment, prompting organizations to reassess supplier footprints and to explore alternative procurement pathways. As a result, manufacturers have increasingly emphasized supplier qualification redundancy, nearshoring of key components, and strategic inventory management to preserve production continuity.

The cumulative effect has been a reshaping of supplier relationships and a renewed focus on total landed cost rather than unit price alone. Companies now place greater emphasis on supplier performance metrics, lead-time reliability, and resilience planning to mitigate the operational impacts of trade measures. In addition, the tariffs have accelerated discussions around manufacturing localization as organizations weigh the trade-offs between capital investment in regional facilities and the flexibility afforded by third-party manufacturing partnerships.

Importantly, the policy environment has stimulated innovation in procurement and logistics, such as consolidated shipping, bonded warehousing, and aggregated purchasing consortia. These adaptations are enabling some manufacturers to partially offset increased import costs while maintaining regulatory compliance and quality standards. Looking ahead, leaders are integrating tariff scenario planning into capital and supply chain strategies to maintain agility and protect continuity of clinical and commercial supply.

In-depth segmentation intelligence revealing how vector biology, workflow architecture, delivery modalities, enabling technologies, therapeutic indications, applications, and end-user profiles dictate manufacturing strategy

Segmentation analysis reveals nuanced drivers and operational priorities that vary by vector biology, workflow stage, delivery modality, enabling technology, therapeutic focus, application, and end user profile. Based on Vector Type, the market is studied across Adenoviral Vectors, Baculoviral Vectors, Herpes Simplex Vectors, Lentiviral Vectors, Plasmid DNA, and Retrovirus, each presenting distinct tropism, payload capacity, and downstream purity challenges that influence process design and analytics needs. Based on Workflow, the market is studied across Downstream Processing and Upstream Processing, where Downstream Processing is further studied across Formulation and Purification and Upstream Processing is further studied across Bioreactors, Cell Culture Systems, and Media Formulations; this division underscores how upstream choices such as cell culture systems directly affect downstream purification loads and formulation stability requirements.

Based on Delivery Method, the market is studied across Ex Vivo and In Vivo, with the Ex Vivo further studied across Cell Re-infusion and Cell Transduction and the In Vivo further studied across Direct Injection, Intravenous Route, and Oral Administration; these delivery distinctions drive product specifications, sterility controls, and cold chain demands, influencing manufacturing batch sizes and release strategies. Based on Technology, the market is studied across Purification Techniques and Transfection Methods, where the Purification Techniques category is further studied across Chromatography and Ultrafiltration and the Transfection Methods category is further studied across Chemical-Based and Electroporation approaches; technology choices determine process footprint, consumables consumption, and validation complexity.

Based on Disease Indication, the market is studied across Cardiovascular Diseases, Genetic Disorders, Infectious Diseases, and Metabolic Disorders, each with different patient populations, route-of-administration preferences, and regulatory considerations that shape development timelines. Based on Application, the market is studied across Gene Therapy, Oncology Research, and Vaccinology, where Gene Therapy is further studied across Inherited Disorders, Oncological Disorders, and Single Gene Mutations, Oncology Research is further studied across Gene Inactivation, Oncolytic Virotherapy, and Tumor Suppressor Genes, and Vaccinology is further studied across Cancer Vaccines, Infectious Diseases, and Zoonotic Diseases; these application-level distinctions inform the acceptable risk-benefit profile and, consequently, the manufacturing rigor and batch release criteria. Based on End User, the market is studied across Biotechnology Companies, Pharmaceutical Companies, and Research Institutions, where Biotechnology Companies is further studied across Large Enterprises and Start-Ups, Pharmaceutical Companies is further studied across Manufacturing and Research and Development, and Research Institutions is further studied across Academic Laboratories and Government Labs; each end-user segment exhibits different tolerances for capital intensity, preferred partnership models, and expectations for technical support and regulatory guidance.

Synthesizing these segmentation insights highlights that manufacturing strategies cannot be one-size-fits-all. Vector biology informs process constraints, workflow segmentation pinpoints critical handoffs that impact yield and quality, delivery method determines stability and dose strategy, technology selection dictates capital and operational expenditure profiles, disease indication frames regulatory and clinical risks, application context sets the commercial cadence, and end-user archetypes drive partnership structures and investment horizons. Consequently, organizations planning capacity expansion, technology adoption, or market entry must align choices across these segmentation dimensions to optimize product integrity, time-to-clinic, and downstream scalability.

Strategic regional perspectives on manufacturing capacity, regulatory complexity, and supply chain resilience across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets

Regional dynamics continue to exert a decisive influence on manufacturing strategy, regulatory interactions, and commercial deployment. In the Americas, robust venture funding, advanced clinical pipelines, and established contract manufacturing infrastructures support rapid program advancement, yet cost pressures and trade policy considerations require careful supply chain design. In Europe, Middle East & Africa, regulatory harmonization efforts coexist with diverse national requirements, prompting manufacturers to build flexible quality systems and leverage regional CMO networks to navigate heterogeneous approval pathways. In the Asia-Pacific region, investments in bioprocessing capabilities and a growing base of domestic suppliers have expanded local manufacturing options, accelerating localized production for regional clinical studies and commercial supply.

Across these regions, talent availability, infrastructure maturity, and policy frameworks vary significantly, which affects timelines for facility qualification, material sourcing, and cross-border regulatory submissions. Consequently, strategic planners must account for regional nuances when selecting manufacturing partners, locating capacity, and designing distribution channels. For global programs, a hybrid approach that combines regional manufacturing nodes with centralized analytic and quality oversight often yields the best balance of responsiveness, cost control, and compliance.

A strategic assessment of the competitive landscape showing how process expertise, integrated platform providers, and collaborative partnerships are reshaping capability and capacity competition

Key companies in the viral vector manufacturing ecosystem are shaping the industry through differentiated capabilities in process development, scale-up, analytical services, and manufacturing capacity. Established contract manufacturers continue to expand capacity and technical offerings, integrating advanced purification platforms and modular cleanroom solutions to meet varied client needs. Biotech innovators are simultaneously pushing the envelope in vector design and transfection chemistries, which has created demand for specialized process development partnerships and bespoke analytical methods.

In addition, technology providers supplying bioreactors, single-use systems, chromatography resins, and ultrafiltration modules play a pivotal role in defining operational efficiency and cost structure. Companies offering end-to-end solutions that couple upstream optimization with downstream robustness and formulation expertise are gaining traction among organizations pursuing accelerated development timelines. Moreover, cross-sector collaborations between pharmaceutical firms, academic centers, and government laboratories are becoming more frequent, enabling shared access to specialized equipment, rare expertise, and manufacturing capacity during critical program stages.

Taken together, the competitive landscape favors organizations that can demonstrate technical depth, flexible capacity models, and proven quality systems; companies that invest in interoperability of platforms, digital process control, and robust supplier ecosystems will be best positioned to capture emerging opportunities across therapeutic areas.

Actionable operational and strategic recommendations for leaders to strengthen resilience, quality systems, regional capacity choices, and technology investments for viral vector manufacturing

To convert insight into operational advantage, industry leaders should prioritize a set of targeted actions focused on resilience, quality, and strategic investment. First, align platform selection with anticipated clinical and commercial profiles, ensuring that vector type and delivery method choices are supported by validated upstream and downstream train designs. Second, invest in supplier qualification and dual-sourcing strategies for critical consumables and equipment to mitigate the impacts of trade measures and logistical disruptions. Third, accelerate adoption of process analytical technology and digital control systems to reduce cycle variability and enable data-driven release strategies.

In parallel, leaders should evaluate the merits of regional capacity diversification by balancing near-term agility with longer-term cost considerations, and pursue flexible partnership models such as toll manufacturing and capacity reservation agreements. Workforce development is equally critical: build multidisciplinary teams that bring together process scientists, regulatory experts, and supply chain strategists to ensure that decisions are robust across the product lifecycle. Finally, integrate scenario-based planning for regulatory changes and tariff fluctuations into capital and operational planning cycles to preserve optionality and reduce risk to patient supply.

By executing these recommendations, organizations can strengthen their operational resilience, shorten development timelines, and improve the predictability of manufacturing outcomes while safeguarding product quality and regulatory compliance.

A transparent, multi-method research approach integrating primary interviews, technical literature review, and cross-case analysis to produce actionable manufacturing insights

This research synthesis draws on a multi-method approach combining primary interviews, technical literature review, and comparative analysis of regulatory guidance and industry practice. Primary inquiry involved structured conversations with process development scientists, manufacturing leaders, quality assurance professionals, and procurement executives to surface practical constraints, adoption drivers, and operational priorities. Secondary sources included peer-reviewed journals, technical white papers, and public regulatory documents to ensure that technological and compliance assertions reflect current standards and scientific consensus.

Qualitative synthesis was complemented by cross-case analysis of manufacturing approaches to identify commonalities in platform selection, workflow handoffs, and risk mitigation strategies. Special attention was given to triangulating claims about technology performance with independent technical reports and vendor specifications to avoid undue reliance on promotional materials. Throughout the analysis, confidentiality was maintained for proprietary data shared by participants, and interpretations were calibrated to emphasize generalizable insights rather than firm-specific claims.

A concise, forward-looking conclusion summarizing strategic imperatives for operationalizing robust, scalable, and compliant viral vector manufacturing

In summary, viral vector manufacturing is transitioning from artisanal, program-specific production toward more industrialized, quality-centric operations that support diverse therapeutic modalities. This transition is being shaped by advances in purification and transfection technologies, evolving regulatory expectations, and commercial dynamics that demand agility across development and supply. Tariff-induced procurement shifts have highlighted the importance of resilient supplier networks and regional manufacturing strategies, while segmentation analysis underscores that optimal process designs must be tailored to vector type, workflow architecture, delivery method, technology choice, disease indication, application, and end-user needs.

For decision-makers, the imperative is clear: invest in flexible, data-driven manufacturing platforms, foster strategic supplier relationships, and build cross-functional capabilities to bridge research and large-scale production. By doing so, organizations can reduce technical and regulatory risk, improve time-to-clinic, and create a foundation for sustainable commercial supply of vector-based therapies. The path forward requires disciplined execution, informed technology choices, and a strategic balance between in-house capabilities and external partnerships.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Viral Vector Manufacturing Market, by Vector Type

  • 8.1. Adenoviral Vectors
  • 8.2. Baculoviral Vectors
  • 8.3. Herpes Simplex Vectors
  • 8.4. Lentiviral Vectors
  • 8.5. Plasmid DNA
  • 8.6. Retrovirus

9. Viral Vector Manufacturing Market, by Workflow

  • 9.1. Downstream Processing
    • 9.1.1. Formulation
    • 9.1.2. Purification
  • 9.2. Upstream Processing
    • 9.2.1. Bioreactors
    • 9.2.2. Cell Culture Systems
    • 9.2.3. Media Formulations

10. Viral Vector Manufacturing Market, by Delivery Method

  • 10.1. Ex Vivo
    • 10.1.1. Cell Re-infusion
    • 10.1.2. Cell Transduction
  • 10.2. In Vivo
    • 10.2.1. Direct Injection
    • 10.2.2. Intravenous Route
    • 10.2.3. Oral Administration

11. Viral Vector Manufacturing Market, by Technology

  • 11.1. Purification Techniques
    • 11.1.1. Chromatography
    • 11.1.2. Ultrafiltration
  • 11.2. Transfection Methods
    • 11.2.1. Chemical-Based
    • 11.2.2. Electroporation

12. Viral Vector Manufacturing Market, by Disease Indication

  • 12.1. Cardiovascular Diseases
  • 12.2. Genetic Disorders
  • 12.3. Infectious Diseases
  • 12.4. Metabolic Disorders

13. Viral Vector Manufacturing Market, by Application

  • 13.1. Gene Therapy
    • 13.1.1. Inherited Disorders
    • 13.1.2. Oncological Disorders
    • 13.1.3. Single Gene Mutations
  • 13.2. Oncology Research
    • 13.2.1. Gene Inactivation
    • 13.2.2. Oncolytic Virotherapy
    • 13.2.3. Tumor Suppressor Genes
  • 13.3. Vaccinology
    • 13.3.1. Cancer Vaccines
    • 13.3.2. Infectious Diseases
    • 13.3.3. Zoonotic Diseases

14. Viral Vector Manufacturing Market, by End User

  • 14.1. Biotechnology Companies
    • 14.1.1. Large Enterprises
    • 14.1.2. Start-Ups
  • 14.2. Pharmaceutical Companies
    • 14.2.1. Manufacturing
    • 14.2.2. Research and Development
  • 14.3. Research Institutions
    • 14.3.1. Academic Laboratories
    • 14.3.2. Government Labs

15. Viral Vector Manufacturing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Viral Vector Manufacturing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Viral Vector Manufacturing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Viral Vector Manufacturing Market

19. China Viral Vector Manufacturing Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. ABL Inc.
  • 20.6. Batavia Biosciences B.V. by CJ Cheiljedang
  • 20.7. Biovian Oy
  • 20.8. Charles River Laboratories International, Inc.
  • 20.9. Creative Biogene
  • 20.10. Danaher Corporation
  • 20.11. FinVector Oy
  • 20.12. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 20.13. GE HealthCare Technologies, Inc.
  • 20.14. Genezen Laboratories, Inc.
  • 20.15. Kaneka Eurogentec S.A.
  • 20.16. Lonza Group Ltd.
  • 20.17. MaxCyte, Inc.
  • 20.18. Merck KGaA
  • 20.19. Miltenyi Biotec GmbH
  • 20.20. Novartis AG
  • 20.21. Oxford Biomedica PLC
  • 20.22. Sanofi SA
  • 20.23. Sirion-Biotech GmbH
  • 20.24. Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • 20.25. Takara Bio Inc.
  • 20.26. Thermo Fisher Scientific Inc.
  • 20.27. uniQure N.V.
  • 20.28. VGXI, Inc. by GeneOne Life Science
  • 20.29. Waisman Biomanufacturing
  • 20.30. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LARGE ENTERPRISES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LARGE ENTERPRISES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY START-UPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY START-UPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY START-UPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GOVERNMENT LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GOVERNMENT LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2032 (USD MILLION)
  • TABLE 286. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 290. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 29